Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 14/20 | 0.43 |
| ▸ | HTR2C | P28335 | 13/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697142 | 0.90 | HTR2A (0.44) | HTR2AHTR2C | |
| SCHEMBL4696649 | 0.85 | PRKCZ (0.45) | HTR2AHTR2C | |
| SCHEMBL5242619 | 0.83 | HTR2A (0.47) | HTR2AHTR2CAKT1 | |
| SCHEMBL4697467 | 0.82 | CHEK2 (0.46) | CHEK2HTR2AHTR2CIRAK4 | |
| SCHEMBL5243165 | 0.80 | HTR2A (0.47) | CHEK2HTR2AHTR2C | |
| SCHEMBL3905583 | 0.80 | HTR2A (0.49) | HTR2AHTR2C | |
| SCHEMBL1165917 | 0.80 | HTR2A (0.72) | HTR2AHTR2C | |
| SCHEMBL4697500 | 0.79 | HTR2A (0.55) | HTR2AHTR2C | |
| SCHEMBL4695702 | 0.78 | HTR2A (0.66) | HTR2AHTR2C | |
| SCHEMBL1165851 | 0.77 | HTR2A (0.48) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10781180-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190263757-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20160304463-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-8785441-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130237540-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2013-09-12 | — | — | US | disclosed |
| EP-1978019-A1 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | Arena Pharmaceuticals, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| EP-1833799-B1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT-2a SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070244086-A1 | 3-Phenyl-Pyrazole Derivatives as Modulators of the 5-Ht2A Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. | 2007-10-18 | — | — | US | disclosed |
| EP-1833799-A2 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT-2a SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070207994-A1 | 3-Phenyl-pyrazole derivatives as modulators of the 5-HT2a serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| WO-2006055734-A2 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237540-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR3A, HTR3B | CHEK2 4498/4885HTR2A 4/4885HTR2C 5/4885 |
| US-20160304463-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR3A, HTR2A | CHEK2 4426/4885HTR2A 3/4885HTR2C 5/4885 |
| US-20070207994-A1 | 3-Phenyl-pyrazole derivatives as modulators of the 5-HT2a serotonin receptor useful for the treatment of disorders related thereto | HTR5A, HTR3A, HTR3B | CHEK2 4498/4885HTR2A 4/4885HTR2C 5/4885 |
| US-20190263757-A1 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR3A, HTR2A | CHEK2 4426/4885HTR2A 3/4885HTR2C 5/4885 |
| US-10781180-B2 | 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | HTR5A, HTR3A, HTR2A | CHEK2 4426/4885HTR2A 3/4885HTR2C 5/4885 |
| US-20070244086-A1 | 3-Phenyl-Pyrazole Derivatives as Modulators of the 5-Ht2A Serotonin Receptor Useful for the Treatment of Disorders Related Thereto | HTR5A, HTR3A, HTR2A | CHEK2 4426/4885HTR2A 3/4885HTR2C 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.